

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original): Use of compound which is an imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- and oxazolo-quinolinamine or pyridinamine, imidazonaphthyridine or tetrahydroimidazonaphthyridine amine in the manufacture of a medicament to enhance an immune response to an antigen, wherein the compound is administered topically or transdermally to the individual 12 to 36 hours after a nucleic acid vaccine is administered, and wherein the nucleic acid vaccine comprises a nucleotide sequence that encodes an HIV-1 gag protein or fragment containing a gag epitope thereof and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter.
  
2. (Original): Use of a nucleotide sequence that encodes an HIV-1 gag protein or fragment containing a gag epitope thereof and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter in the manufacture of a nucleic acid vaccine, wherein 12 to 36 hours subsequent to the administration of the nucleic acid vaccine to an individual a compound which is an imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- and oxazolo-quinolinamine or pyridinamine, imidazonaphthyridine or tetrahydroimidazonaphthyridine amine is administered topically or transdermally to the individual.

3. (Currently Amended): Use according to claim 1-~~or 2~~ wherein the compound is an imidazoquinoline.

4. (Currently Amended): Use according to claim 1-~~or 2~~ wherein the compound is imiquimod or resiquimod.

5. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the nucleic acid vaccine is administered topically or transdermally.

6. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the nucleic acid vaccine is administered in the form of particles.

7. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the compound is administered in the form of particles.

8. (Currently Amended): Use according to claim 6-~~or 7~~ wherein the nucleic acid vaccine or compound is coated on a core carrier.

9. (Currently Amended): Use according to ~~any one of claims 6 to 8~~ claim 6 wherein the nucleic acid vaccine or compound is administered using a needleless syringe.

10. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 in which the compound is administered in the form of a cream.

11. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the administration of the antigen or polynucleotide is repeated to provide a prime and booster administration.

12. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the second antigen is selected from the group consisting of: Nef, RT or a fragment containing an epitope of Nef or RT.

13. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the gag protein comprises p17.

14. (Original): Use according to claim 13 wherein the gag protein additionally comprises p24.

15. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the gag sequence is codon optimised to resemble the codon usage in a highly expressed human gene.

16. (Currently Amended): Use according to ~~any one claims 12 to 15~~ claim 12 wherein the RT sequence or fragment thereof is codon optimised to resemble a highly expressed human gene.

17. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the nucleotide sequence encodes a Nef protein or epitope thereof.

18. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the nucleotide sequence is selected from the group

-Gag (p17,p24) Nef truncate

-Gag (p17,p24) (codon optimised)Nef(truncate)

-Gag (p17,p24) RT Nef (truncate)

Gag (p17,p24) codon optimised RT Nef (truncate)

-Gag (p17,p24) codon optimised RT codon optimised Nef truncate.

19. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the heterologous promoter is the minimal promoter from HCMV IE gene.

20. (Original): Use according to claim 19 wherein the 5' of the promoter comprises exon 1.

21. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the nucleic acid sequence is in the form of a double stranded DNA plasmid.

22. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein the nucleic acid sequence encodes Gag (or a fragment thereof which comprises an epitope) and RT (or a fragment thereof which comprises an epitope) and Nef (or a fragment thereof which comprises an epitope) in any order.

23. (Original): Use according to claim 22 wherein the nucleic acid encodes the proteins, or fragments thereof, in the sequence Nef-RT-Gag, RT-Nef-Gag or RT-Gag-Nef.

24. (Currently Amended): Use according to ~~any one of the preceding claims~~ claim 1 wherein at least one of the proteins which is encoded by the nucleic acid is a fusion protein.

25. (Original): A product containing (i) a nucleic acid vaccine that comprises a nucleotide sequence that encodes an HIV-1 gag protein or fragment containing a gag epitope thereof and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter, and (ii) a compound which is an imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- and oxazolo-quinolinamine or pyridinamine, imidazonaphthyridine or tetrahydroimidazonaphthyridine amine for sequential use, wherein the compound is administered topically or transdermally 12 to 36 hours after administration of the nucleic acid vaccine.

26. (Original): Method enhancing in an individual an immune response generated by a nucleic acid vaccine, said method comprising administering a compound which is an imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- or oxazolo-quinolinamine or pyridinamines, imidazonaphthyridine or tetrahydroimidazonaphthyridine amine, wherein the compound is

administered topically or transdermally to the individual 12 to 36 hours after the nucleic acid vaccine is administered, and wherein the nucleic acid vaccine comprises a nucleotide sequence that encodes an HIV-1 gag protein or fragment containing a gag epitope thereof and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter.

27. (Original): Method of preventing or treating HIV infection or AIDS comprising administering a nucleic acid vaccine that comprises a nucleotide sequence that encodes an HIV-1 gag protein or fragment containing a gag epitope thereof and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter, and 12 to 36 hours subsequent to the administration of the nucleic acid vaccine administering a compound as defined in claim 26, wherein the compound is administered topically or transdermally.